Georgia Ravitz is a partner in the life sciences practice of Wilson Sonsini Goodrich & Rosati, where she specializes in FDA regulatory, healthcare, and consumer products innovation and compliance. In particular, she focuses on food and drug law and regulatory policy governing the regulation and promotion of medical devices, pharmaceuticals (including OTCs), health and beauty aids (cosmetics), dietary supplements, vitamins, food and agribusiness, tobacco and e-cigarettes, cannabis, and a wide variety of consumer goods and emerging consumer technologies. She counsels U.S. and foreign manufacturers, distributors, retailers, and importers of regulated products in all phases of their product lifecycle, from innovation through product commercialization and ongoing post-market compliance.
Prior to joining the firm, Georgia was a senior partner in the FDA and advertising practices of Arent Fox in Washington, D.C., where she led the firm's consumer product safety practice. She is a frequent speaker at conferences and events, and a regular contributor to leading trade and consumer media outlets.
Georgia Ravitz is a partner in the life sciences practice of Wilson Sonsini Goodrich & Rosati, where she specializes in FDA regulatory, healthcare, and consumer products innovation and compliance. In particular, she focuses on food and drug law and regulatory policy governing the regulation and promotion of medical devices, pharmaceuticals (including OTCs), health and beauty aids (cosmetics), dietary supplements, vitamins, food and agribusiness, tobacco and e-cigarettes, cannabis, and a wide variety of consumer goods and emerging consumer technologies. She counsels U.S. and foreign manufacturers, distributors, retailers, and importers of regulated products in all phases of their product lifecycle, from innovation through product commercialization and ongoing post-market compliance.
Prior to joining the firm, Georgia was a senior partner in the FDA and advertising practices of Arent Fox in Washington, D.C., where she led the firm's consumer product safety practice. She is a frequent speaker at conferences and events, and a regular contributor to leading trade and consumer media outlets.
Co-author, "New Reimbursement Rules Will Likely Impact Digital Health and Telemedicine," Wilson Sonsini Alert, December 2, 2022
Co-author with D. Hoffmeister, J. Ravitz, and E. Yin, "Prescription Drug Provisions in the Build Back Better Act," Wilson Sonsini Alert, January 10, 2022
Co-author with P. Gadiock, D. Hoffmeister, J. Ravitz, and E. Yin, "FDA Issues Draft Transition Plans for Medical Devices Commercialized Pursuant to EUA or Enforcement Discretion Policy During COVID-19 Emergency," Wilson Sonsini Alert, December 23, 2021
Moderator, “FDA Regulation of Xenotransplantation for Medical Use,” Food and Drug Law Institute Annual Conference, May 18, 2023
Co-presenter, “Introduction to Medical Device Law and Regulation, Promotion and Advertising,” Food and Drug Law Institute/Center for Devices and Radiological Health, December 9, 2022
Co-presenter, “Introduction to Medical Device Law and Regulation, Promotion and Advertising,” Food and Drug Law Institute/Center for Devices and Radiological Health, August 10, 2022
“The Regulation of Cosmetics,” Food and Drug Law Institute’s Introduction to Food Law and Regulation, March 18, 2021
“Regulatory and Start-Up Considerations for Early-Stage Companies,” Future Food-Tech Conference, March 11, 2021
“Path to Regulatory Approval – A New Era?” Edison Open House: Global Healthcare, January 19, 2021
“Georgetown FDLI Lunch & Learn: CBD Regulation,” Food and Drug Law Institute, October 30, 2020
"Regulatory Changes Impacting the Commercialization of Cannabis—Insights About FDA," CiConnect CannaMed/Tech, May 1, 2019
Co-author, "New Reimbursement Rules Will Likely Impact Digital Health and Telemedicine," Wilson Sonsini Alert, December 2, 2022
Co-author with D. Hoffmeister, J. Ravitz, and E. Yin, "Prescription Drug Provisions in the Build Back Better Act," Wilson Sonsini Alert, January 10, 2022
Co-author with P. Gadiock, D. Hoffmeister, J. Ravitz, and E. Yin, "FDA Issues Draft Transition Plans for Medical Devices Commercialized Pursuant to EUA or Enforcement Discretion Policy During COVID-19 Emergency," Wilson Sonsini Alert, December 23, 2021
Moderator, “FDA Regulation of Xenotransplantation for Medical Use,” Food and Drug Law Institute Annual Conference, May 18, 2023
Co-presenter, “Introduction to Medical Device Law and Regulation, Promotion and Advertising,” Food and Drug Law Institute/Center for Devices and Radiological Health, December 9, 2022
Co-presenter, “Introduction to Medical Device Law and Regulation, Promotion and Advertising,” Food and Drug Law Institute/Center for Devices and Radiological Health, August 10, 2022
“The Regulation of Cosmetics,” Food and Drug Law Institute’s Introduction to Food Law and Regulation, March 18, 2021
“Regulatory and Start-Up Considerations for Early-Stage Companies,” Future Food-Tech Conference, March 11, 2021
“Path to Regulatory Approval – A New Era?” Edison Open House: Global Healthcare, January 19, 2021
“Georgetown FDLI Lunch & Learn: CBD Regulation,” Food and Drug Law Institute, October 30, 2020
"Regulatory Changes Impacting the Commercialization of Cannabis—Insights About FDA," CiConnect CannaMed/Tech, May 1, 2019